Compare Dishman Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs IPCA LABS - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA IPCA LABS DISHMAN PHARMA/
IPCA LABS
 
P/E (TTM) x 25.1 23.1 108.8% View Chart
P/BV x 3.3 4.5 74.8% View Chart
Dividend Yield % 0.7 0.1 633.1%  

Financials

 DISHMAN PHARMA   IPCA LABS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
IPCA LABS
Mar-18
DISHMAN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs374695 53.8%   
Low Rs129400 32.2%   
Sales per share (Unadj.) Rs197.8260.2 76.0%  
Earnings per share (Unadj.) Rs21.219.0 111.8%  
Cash flow per share (Unadj.) Rs34.733.1 105.0%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.80.2 435.3%  
Book value per share (Unadj.) Rs179.9213.0 84.4%  
Shares outstanding (eoy) m80.69126.20 63.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.1 60.4%   
Avg P/E ratio x11.928.9 41.1%  
P/CF ratio (eoy) x7.216.6 43.7%  
Price / Book Value ratio x1.42.6 54.4%  
Dividend payout %9.45.3 178.9%   
Avg Mkt Cap Rs m20,30669,120 29.4%   
No. of employees `0000.813.3 6.3%   
Total wages/salary Rs m5,3557,359 72.8%   
Avg. sales/employee Rs Th19,252.72,477.4 777.1%   
Avg. wages/employee Rs Th6,459.5555.2 1,163.4%   
Avg. net profit/employee Rs Th2,064.1180.6 1,142.6%   
INCOME DATA
Net Sales Rs m15,96132,836 48.6%  
Other income Rs m265418 63.5%   
Total revenues Rs m16,22633,254 48.8%   
Gross profit Rs m4,1034,505 91.1%  
Depreciation Rs m1,0911,777 61.4%   
Interest Rs m944240 393.2%   
Profit before tax Rs m2,3342,905 80.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624511 122.0%   
Profit after tax Rs m1,7112,394 71.5%  
Gross profit margin %25.713.7 187.4%  
Effective tax rate %26.717.6 151.9%   
Net profit margin %10.77.3 147.0%  
BALANCE SHEET DATA
Current assets Rs m11,01819,455 56.6%   
Current liabilities Rs m9,51710,076 94.5%   
Net working cap to sales %9.428.6 32.9%  
Current ratio x1.21.9 60.0%  
Inventory Days Days11098 112.9%  
Debtors Days Days3567 52.0%  
Net fixed assets Rs m16,30420,260 80.5%   
Share capital Rs m161252 63.9%   
"Free" reserves Rs m12,90726,633 48.5%   
Net worth Rs m14,51626,886 54.0%   
Long term debt Rs m4,1892,340 179.0%   
Total assets Rs m29,80541,173 72.4%  
Interest coverage x3.513.1 26.5%   
Debt to equity ratio x0.30.1 331.6%  
Sales to assets ratio x0.50.8 67.1%   
Return on assets %8.96.4 139.2%  
Return on equity %11.88.9 132.4%  
Return on capital %17.510.8 162.9%  
Exports to sales %24.847.6 52.0%   
Imports to sales %3.714.9 25.1%   
Exports (fob) Rs m3,95615,642 25.3%   
Imports (cif) Rs m5964,884 12.2%   
Fx inflow Rs m4,95215,642 31.7%   
Fx outflow Rs m6974,884 14.3%   
Net fx Rs m4,25510,759 39.5%   
CASH FLOW
From Operations Rs m2,7863,411 81.7%  
From Investments Rs m-1,529-1,354 112.9%  
From Financial Activity Rs m-941-1,304 72.2%  
Net Cashflow Rs m316753 42.0%  

Share Holding

Indian Promoters % 61.4 45.9 133.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 11.4 32.5%  
FIIs % 12.7 25.3 50.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.4 127.0%  
Shareholders   46,261 36,892 125.4%  
Pledged promoter(s) holding % 35.8 2.1 1,671.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - TORRENT PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS